FDA Authorizes Pritelivir Oral Tablets for Immunocompromised HSV Patients

The FDA has approved pritelivir (Hovilpri) oral tablets to treat mucocutaneous lesions caused by herpes simplex virus (HSV) in adults. This new treatment option is particularly significant for immunocompromised patients who have not responded to existing therapies like acyclovir, valacyclovir, or famciclovir, addressing an unmet need for this common viral infection.